BortezomibBortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM.
IC50 value: 0.6 nM (Ki) [1]
Target: 20S proteasome
in vitro: The average growth inhibition of 50% value for Bortezomib across the entire panel of 60 cancer cell lines derived from multiple human tumors from the US National Cancer Institute (NCI) is 7 nM.